3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
3
Unknown
2
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Sarcoma
1
Conditions
Carcinoma, Basal Cell
2
Sarcoma, Kaposi
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Interventions
Injections
54
Cisplatin
49
Paclitaxel
48
Carboplatin
43
Gemcitabine
38
pembrolizumab
36
Docetaxel
36
Capecitabine
36
Drug Therapy
34
anlotinib
25
Bevacizumab
25
Fluorouracil
24
Cyclophosphamide
24
icotinib
23
Oxaliplatin
20
fludarabine
19
Pemetrexed
17
Leucovorin
16
Irinotecan
16
Temozolomide
14
Nivolumab
14
Doxorubicin
14
Cetuximab
14
camrelizumab
13
apatinib
13
Trastuzumab
12
Rituximab
11
Fulvestrant
11
Etoposide
11
tesetaxel
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
INDUSTRY
×
daromun
×
Clear all
NCT04362722
2023-10-10
DUNCAN
Philogen S.p.A.
Phase 2
Unknown
40 enrolled
NCT05329792
2023-10-06
IntriNSiC
Philogen S.p.A.
Phase 2
Unknown
70 enrolled